Therapeutic Class

Testing times: WuXi ATU investments ready to support CGT cascade

Testing times: WuXi ATU investments ready to support CGT cascade Testing times: WuXi ATU investments ready to support CGT cascade

WuXi Advanced Therapies has highlighted its CGT testing capabilities in preparation for as many as 200 products reaching the market.

Oct 4, 2022

|

20 Min View

Supply chain weight grows as CGTs reach ‘critical inflection point’

Therapeutic Class

Supply chain weight grows as CGTs reach ‘critical inflection point’Supply chain weight grows as CGTs reach ‘critical inflection point’

byGareth Macdonald

Oct 4, 2022

1 Min Read

Thermo Fisher launches Dynabeads tech to support mRNA production

Therapeutic Class

Thermo Fisher launches Dynabeads tech to support mRNA production Thermo Fisher launches Dynabeads tech to support mRNA production

byMillie Nelson

Oct 4, 2022

1 Min Read

FDA creates advanced therapies ‘super office’ to meet higher demand

FDA creates advanced therapies ‘super office’ to meet higher demand FDA creates advanced therapies ‘super office’ to meet higher demand

byGareth Macdonald

Oct 3, 2022

1 Min Read

With MA plant operational, CRISPR lauds allogeneic cell therapy approach

Therapeutic Class

With MA plant operational, CRISPR lauds allogeneic cell therapy approach With MA plant operational, CRISPR lauds allogeneic cell therapy approach

Oct 3, 2022

1 Min Read

Platforms are pivotal to pandemic speed, says BMS

Upstream & Downstream Processing

Platforms are pivotal to pandemic speed, says BMS Platforms are pivotal to pandemic speed, says BMS

byMillie Nelson

Sep 29, 2022

1 Min Read

Polyplus bolsters mRNA portfolio with LNP-alternative reagent

Therapeutic Class

Polyplus bolsters mRNA portfolio with LNP-alternative reagent

Polyplus bolsters mRNA portfolio with LNP-alternative reagent

byMillie Nelson, Editor

Gene therapy firms must consider patients when choosing rAAV production systems

Therapeutic Class

Gene therapy firms must consider patients when choosing rAAV production systems

Gene therapy firms must consider patients when choosing rAAV production systems

byGareth Macdonald

Bluebird Skysona approval: ‘A resurgence for HSC gene therapy’

Bluebird Skysona approval: ‘A resurgence for HSC gene therapy’

Bluebird Skysona approval: ‘A resurgence for HSC gene therapy’

byDan Stanton, Editorial director

AbbVie: Manufacturing consistency will affect Humira biosimilar uptake

AbbVie: Manufacturing consistency will affect Humira biosimilar uptake

AbbVie: Manufacturing consistency will affect Humira biosimilar uptake

byDan Stanton, Editorial director

BMS confident Breyanzi capacity issues will be resolved in 2023

BMS confident Breyanzi capacity issues will be resolved in 2023

BMS confident Breyanzi capacity issues will be resolved in 2023

byDan Stanton, Editorial director

Novel Dual-Plasmid Transfection System Improves Titer And Product Quality In AAV Manufacturing

Sponsored Content

Novel Dual-Plasmid Transfection System Improves Titer And Product Quality In AAV Manufacturing

Novel Dual-Plasmid Transfection System Improves Titer And Product Quality In AAV Manufacturing

byOxford Biomedica

Cali court’s stem cell clinic ruling ‘flawed’ and ‘dangerous,’ says CGT advocacy group

Cali court’s stem cell clinic ruling ‘flawed’ and ‘dangerous,’ says CGT advocacy group

Cali court’s stem cell clinic ruling ‘flawed’ and ‘dangerous,’ says CGT advocacy group

byDan Stanton, Editorial director

Takeda and Cryoport team to standardize cell therapy supply chain

Therapeutic Class

Takeda and Cryoport team to standardize cell therapy supply chain

Takeda and Cryoport team to standardize cell therapy supply chain

byDan Stanton, Editorial director

Orca Bio taking inhouse approach to cell therapy with Sacramento plant

Therapeutic Class

Orca Bio taking inhouse approach to cell therapy with Sacramento plant

Orca Bio taking inhouse approach to cell therapy with Sacramento plant

byDan Stanton, Editorial director

Neukio Bio raises $50m for allogenic CAR-T therapies

Neukio Bio raises $50m for allogenic CAR-T therapies

Neukio Bio raises $50m for allogenic CAR-T therapies

byRichard Daverman

Ilya secures IP position for modified bacteria immunotherapy candidates

Therapeutic Class

Ilya secures IP position for modified bacteria immunotherapy candidates

Ilya secures IP position for modified bacteria immunotherapy candidates

byGareth Macdonald

#ATE22: The European CGT landscape in Tweets

Therapeutic Class

#ATE22: The European CGT landscape in Tweets

#ATE22: The European CGT landscape in Tweets

Cytiva and Caring Cross to develop CAR-T for HIV

Cytiva and Caring Cross to develop CAR-T for HIV

Cytiva and Caring Cross to develop CAR-T for HIV

byMillie Nelson, Editor

Cell therapy manufacturing studies suggest industry still needs better tech

Therapeutic Class

Cell therapy manufacturing studies suggest industry still needs better tech

Cell therapy manufacturing studies suggest industry still needs better tech

byGareth Macdonald

Bluebird wins US approval for world’s most expensive drug, Zynteglo

Therapeutic Class

Bluebird wins US approval for world’s most expensive drug, Zynteglo

Bluebird wins US approval for world’s most expensive drug, Zynteglo

byDan Stanton, Editorial director

Mayo Clinic and Resilience enter biomanufacturing pact

Mayo Clinic and Resilience enter biomanufacturing pact

Mayo Clinic and Resilience enter biomanufacturing pact

byDan Stanton, Editorial director

Tonix looks to live virus vaccines to prevent the spread of monkeypox

Therapeutic Class

Tonix looks to live virus vaccines to prevent the spread of monkeypox

Tonix looks to live virus vaccines to prevent the spread of monkeypox

byMillie Nelson, Editor

Lilly working ‘around the clock’ to ensure Mounjaro supply

Facilities & Capacity

Lilly working ‘around the clock’ to ensure Mounjaro supply

Lilly working ‘around the clock’ to ensure Mounjaro supply

byDan Stanton, Editorial director

Regenxbio: Inhouse facility a driving force in ‘5x25’ gene therapy ambition

Facilities & Capacity

Regenxbio: Inhouse facility a driving force in ‘5x25’ gene therapy ambition

Regenxbio: Inhouse facility a driving force in ‘5x25’ gene therapy ambition

byDan Stanton, Editorial director

Astellas eyes AMD cell therapy trial restart after manufacturing tweaks

Therapeutic Class

Astellas eyes AMD cell therapy trial restart after manufacturing tweaks

Astellas eyes AMD cell therapy trial restart after manufacturing tweaks

byDan Stanton, Editorial director

Charles River looks to CGT growth to offset ‘bumpiness’ in CDMO biz

Charles River looks to CGT growth to offset ‘bumpiness’ in CDMO biz

Charles River looks to CGT growth to offset ‘bumpiness’ in CDMO biz

byDan Stanton, Editorial director

Plasmid production a plus for Polyplus

Therapeutic Class

Plasmid production a plus for Polyplus

Plasmid production a plus for Polyplus

byMillie Nelson, Editor

Roche inks $110m allogeneic CAR-T deal with Poseida

Therapeutic Class

Roche inks $110m allogeneic CAR-T deal with Poseida

Roche inks $110m allogeneic CAR-T deal with Poseida

byDan Stanton, Editorial director

Further CDMO consolidation in CGT space as RoslinCT and Lykan agree to merge

Further CDMO consolidation in CGT space as RoslinCT and Lykan agree to merge

Further CDMO consolidation in CGT space as RoslinCT and Lykan agree to merge

byDan Stanton, Editorial director

CGT Catapult joins personalized cell therapy consortium

CGT Catapult joins personalized cell therapy consortium

CGT Catapult joins personalized cell therapy consortium

byMillie Nelson, Editor

Core Biogenesis bags $10.5m funding to drive plant-based bioproduction

Facilities & Capacity

Core Biogenesis bags $10.5m funding to drive plant-based bioproduction

Core Biogenesis bags $10.5m funding to drive plant-based bioproduction

byMillie Nelson, Editor

Legend Bio looks to raise $250m in public offering

Legend Bio looks to raise $250m in public offering

Legend Bio looks to raise $250m in public offering

byRichard Daverman

Cell and gene sector could benefit from synthetic standards for flow cytometry

Bioprocess Insider

Cell and gene sector could benefit from synthetic standards for flow cytometry

Cell and gene sector could benefit from synthetic standards for flow cytometry

byGareth Macdonald

Solvias boosts CGT testing with Cergentis acquisition

Solvias boosts CGT testing with Cergentis acquisition

Solvias boosts CGT testing with Cergentis acquisition

Subscribe to receive our monthly print or digital publication

Join our 70,000+ readers. And yes, it's completely free.